Management of Immunotherapy-Related Toxicities in Patients Treated With Immune Checkpoint Inhibitor Therapy
- 2 February 2021
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA
- Vol. 325 (5), 482-483
- https://doi.org/10.1001/jama.2020.17308
Abstract
ICIs are monoclonal antibodies that block inhibitory regulatory proteins. Their use leads to T-cell activation, engaging the immune system to treat the malignancy.2 ICI toxicities, known as IRAEs, range from mild skin rash to fatal myocarditis.3 There are no clinical trials to guide IRAE management, and treatment is based on management of autoimmune diseases outside the ICI setting.Keywords
This publication has 9 references indexed in Scilit:
- Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitisJournal for ImmunoTherapy of Cancer, 2019
- Faculty Opinions recommendation of Myocarditis in patients treated with immune checkpoint inhibitors.Published by H1 Connect ,2019
- Immune Checkpoint Inhibitor Toxicity in 2018JAMA, 2018
- High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanomaCancer, 2018
- Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD AndersonJournal for ImmunoTherapy of Cancer, 2018
- Cancer immunotherapy using checkpoint blockadeScience, 2018
- Myocarditis in Patients Treated With Immune Checkpoint InhibitorsJournal of the American College of Cardiology, 2018
- Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitisCancer Immunology, Immunotherapy, 2017
- Inflammatory arthritis due to immune checkpoint inhibitors: challenges in diagnosis and treatmentImmunotherapy, 2017